Regeneron Pharmaceuticals, Inc.: dividend

REGNNASDAQHealthcare · Pharmaceutical Preparations

Price

$955.47

November 13, 2026Market cap $99.9B

DCF calculator

What Ploutos Investor adds for Regeneron Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Yield

0.39%

$3.70 per share over the last 12 months, at a price of $955.47.

Forward yield0.39%($0.94 a quarter)

FCF coverThe year's free cash flow was 9.9 times the dividend it paid.
9.9x
Payout8% of the last 12 months' earnings went to the dividend.
8%
No cutWithout a cut since 2025, the first year of our figures: the run may be longer.
0+
5-year growthFewer than five years of dividends.
–
Debt / EBITDAMoney that goes to interest does not go to the dividend.
-1.2x

Everything it returns to shareholders

The dividend is one way. The other is buybacks, which reduce the number of shares.

Dividend yield

0.39%

$3.90 a year per $1,000 of shares

Buybacks

3.44%

$34.40 a year per $1,000 of shares

The share count fell by 3.1% over the year.

Total returned

3.83%

$38.30 a year per $1,000 of shares

dividend 10%buybacks 90%

REGN beside the other dividend payers

Where it stands among this week's 968 dividend payers, and in the Healthcare sector. The dot is the company, the white line the median.

Dividend yield0.39%

Above 7% of the payers · median 2.03%

In Healthcare: above 15%, median 0.93%.

Covered by free cash flow9.9x

Above 86% of the payers · median 3.6x

In Healthcare: above 80%, median 4.4x.

Share of earnings paid out8%

Above 6% of the payers · median 35%

In Healthcare: above 6%, median 25%.

Yield, cover and years without a cut for almost 1,000 stocks, in one table.The table

The full analysis

What do Regeneron Pharmaceuticals's filings show?

The dividend is one part of Regeneron Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about REGN's dividend

Didn't find what you were looking for?

Ask us
What is REGN's dividend yield?

Regeneron Pharmaceuticals paid $3.70 per share over the last 12 months. At a price of $955.47, that is a yield of 0.39%.

Does REGN cover its dividend with the cash it makes?

Yes, over the last year. Regeneron Pharmaceuticals's free cash flow was 9.9 times the dividend it paid.

Has REGN ever cut its dividend?

Regeneron Pharmaceuticals has not cut its dividend for 0+ years, in the 1 years of figures we hold.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.GlossaryEvery figure in plain words: what it is, how it is worked out, how to read it.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.